View text source at Wikipedia

Luzindole

Luzindole
Clinical data
ATC code
  • None
Legal status
Legal status
  • In general: non-regulated
Identifiers
  • N-[2-(2-benzyl-1H-indol-3-yl)ethyl]acetamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H20N2O
Molar mass292.382 g·mol−1
3D model (JSmol)
  • O=C(NCCc2c1ccccc1[nH]c2Cc3ccccc3)C
  • InChI=1S/C19H20N2O/c1-14(22)20-12-11-17-16-9-5-6-10-18(16)21-19(17)13-15-7-3-2-4-8-15/h2-10,21H,11-13H2,1H3,(H,20,22)
  • Key:WVVXBPKOIZGVNS-UHFFFAOYSA-N

Luzindole (N-0774; N-acetyl-2-benzyltryptamine), is a drug used in scientific research to study the role of melatonin in the body. Luzindole acts as a selective melatonin receptor antagonist,[1] with approximately 11- to 25-fold greater affinity for the MT2 over the MT1 receptor.[2][3] In animal studies, it has been observed to disrupt the circadian rhythm as well as produce antidepressant effects.[2][4]

Synthesis

[edit]

Although the "hydrogen bomb" method was reported as 54% yield by Dubococvich, Boehringer Sohn achieved 96% for this step. The difference is that B.I. conducted their hydrogenation under normal pressure at 50°C for 5 hours, whereas Dubocovich conducted theirs at 100 lbs/in2 hydrogen heated to 35°C. This proves that the hydrogenation step proceeds favorably under milder conditions.

Patents:[5][6][7]

The Pictet–Spengler reaction between tryptamine [61-54-1] (1) and benzaldehyde gives 1-Phenyl-tetrahydrocarboline [3790-45-2] (2). Catalytic hydrogenation leads to 2-Benzyltryptamine [22294-23-1] (3). Acylation with acetic anhydride only gave 21% yield of Luzindole (4).

Luzindole synthesis 2:[8]

2-iodoaniline [615-43-0] (1) Propargylbenzene [10147-11-2] (2) 2-(3-phenylprop-1-ynyl)aniline, PC85868179 (3) 2-benzylindole [3377-72-8] (4) 1-Dimethylamino-2-nitroethylene [1190-92-7] (5) (6)

One pot Luzindole synthesis:[9]

References

[edit]
  1. ^ Dubocovich ML (September 1988). "Luzindole (N-0774): a novel melatonin receptor antagonist". The Journal of Pharmacology and Experimental Therapeutics. 246 (3): 902–10. PMID 2843633.
  2. ^ a b Dubocovich ML, Yun K, Al-Ghoul WM, Benloucif S, Masana MI (September 1998). "Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms". The FASEB Journal. 12 (12): 1211–20. doi:10.1096/fasebj.12.12.1211. PMID 9737724. S2CID 566199.
  3. ^ Browning C, Beresford I, Fraser N, Giles H (March 2000). "Pharmacological characterization of human recombinant melatonin mt(1) and MT(2) receptors". British Journal of Pharmacology. 129 (5): 877–86. doi:10.1038/sj.bjp.0703130. PMC 1571913. PMID 10696085.
  4. ^ Dubocovich ML, Mogilnicka E, Areso PM (July 1990). "Antidepressant-like activity of the melatonin receptor antagonist, luzindole (N-0774), in the mouse behavioral despair test". European Journal of Pharmacology. 182 (2): 313–25. doi:10.1016/0014-2999(90)90290-M. PMID 2168835.
  5. ^ Margarita L. Dubocovich, et al. WO1989001472A1 ().
  6. ^ Margarita L. Dubocovich, et al., U.S. patent 5,283,343 (1994 to Discovery Therapeutics Inc).
  7. ^ Schroeder Dr Hans-D, et al. DE1445516 (1968 to CH Boehringer Sohn AG and Co KG).
  8. ^ Tsotinis, Andrew; Afroudakis, Pandelis (2008). "Melatonin Receptor Antagonist Luzindole: A Facile New Synthesis". Letters in Organic Chemistry. 5 (6): 507–509. doi:10.2174/157017808785740561. ISSN 1570-1786.
  9. ^ Righi, Marika; Topi, Francesca; Bartolucci, Silvia; Bedini, Annalida; Piersanti, Giovanni; Spadoni, Gilberto (2012). "Synthesis of Tryptamine Derivatives via a Direct, One-Pot Reductive Alkylation of Indoles". The Journal of Organic Chemistry. 77 (14): 6351–6357. doi:10.1021/jo3010028.